Sandbox:Hannan: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 217: Line 217:
|
|
|
|
* Symptoms of adrenal hormones as mentioned in adrenal adenomas
* Constitutional symptoms such as cachexia, night sweats, fever
* Localized symptoms such as abdominal pain, mass, fullness, early satiety
|
|
* Signs of adrenal hormones as mentioned in adrenal adenomas
* Constitutional
* Localized signs such as abdominal mass,abdominal distension
|
|
* N/L
* ↑ Cortisol
* ↑ Aldosterone
* ↑ Androgens 
|
|
|
|

Revision as of 15:57, 1 February 2019

Cortex Product Clinical manifestations Dianosis Gold

standard

Other features
Symptoms Signs Blood & Urine Histopathological Imaging Others
Adenoma Aldosterone[1][2][3][4]
  • Headache
  • Vision problems
  • Muscle cramps
  • Muscle weakness & cramps
  • Numbness
  • Temporary paralysis
  • Polyuria and polydipsia
  • Hypertension
  • Refractory hypertension
  • Hypokalemia
  • Alkalosis
  • ↑ Plasma aldosterone
  • ↓ Plasma Renin
  • ↑ ARR
  • Single or multiple nodules
  • Encapsulated
  • Abundant clear cytoplasm
  • Uniforming nuclei
  • Histopathology may resemble:
    • ZF (large, lipid-laden clear cells)
    • ZG (small, compact cells with moderate amount of lipid)
    • ZR (lipid-sparse cytoplasm)
  • Adrenal mass or nodule
  • Unilateral or bilateral adrenal atrophy
  • Hypodense mass (CT)
  • Iso and low FDG uptake compared with liver (FDG PET/CT)
  • Hyperintense on in-phase and hypointense on oppose-phase (MRI)
  • Fludrocortisone Suppression Testing
  • Oral Sodium Loading
  • Saline Infusion Testing
  • Captopril test
  • Adrenal venous sampling
  • Posture test
  • Genetic testing
  • Immunohistochemical staining
  • Fludrocortisone Suppression Testing
  • Glucocorticoid-Remediable Aldosteronism responds to glucocorticoids
  • Higher cardiovascular and cerebrovascular morbidity
Cortisol[1][5][6][7]
  • Weight gain
  • Growth retardation
  • Headaches
  • Amenorrhea
  • Virilization (rare)
  • Acne
  • Violaceous striae
  • Acanthosis nigricans
  • Sleep disruption
  • Mental changes
  • Muscular weakneness
  • Hypertension
  • Hirsutism
  • Hypogonadism
  • Growth retardation
  • Facial plethora
  • Acne
  • Striae
  • Bruising
  • Acanthosis nigricans
  • Mental changes
  • Muscular weakneness
  • ↑ Plasma cortisol
  • ↑ 24 Hour urinary cortisol
  • ↓ or inappropriately normal plasma ACTH
  • ↑ Blood glucose
  • Yellow fat
  • Brown discoloration
  • Large cells with increased lipid contetnt (zona fasciculata)
  • May contain pigment (lipofuscin)
  • Adjacent atrophied cells
  • Hemorrhage and calcification (Pre-malignant lesions)
  • Adrenal mass or nodule
  • Unilateral or bilateral adrenal atrophy
  • ↑ Fat
  • Hypodense mass (CT)
  • Iso and low FDG uptake compared with liver (FDG PET/CT)
  • Hyperintense on in-phase and hypointense on oppose-phase (MRI)
  • Diurnal plasma cortisol variation
  • Low dose and high dose dexamethasone suppression test
  • Dexamethasone-CRH test
  • Adrenal venous sampling
  • Genetic testing
  • Immunohistochemical staining
  • Dual-energy X-ray absorptiometry
  • N/A
  • Associated with Carney complex
  • Associated with MEN-1
  • Plasma levels of cortisol and ACTH may show false positive and false negative results due to normal diurnal hormonal variation
Androgens[4][8][9][10]
  • Hirsutism
  • Virilization
  • Amenorrhea
  • Precocious puberty
  • Testicular atrophy & diminished libido (male)
  • Clitorimegaly
  • Male pattern baldness
  • Resistant hypertension
  • Gynecomastia
  • ↑ Serum testosterone
  • ↑ Serum androstenedione
  • ↑ Serum dehydroepiandrosterone sulfate (DHEA-S)
  • ↑ urine 17-ketosteroids
  • ↑ plasma and urine estrogens
  • Pale tan to brown
  • Pseudocapsule or the fibrous capsule
  • Nesting, alveolar, cords, trabeculae
  • Eosinophilic cytoplasm
  • May see clear, vacuolated cytoplasm
  • Well-defined
  • Solid mass
  • Homogeneous enhancement (CT contrast)
  • Hyperintense on in-phase and hypointense on oppose-phase (MRI)
  • FSH, LH, prolactin levels
  • Cortisol levels
  • FDG PET/CT
  • Pelvic Ultrasound
  • Adrenal Venous sampling
  • N/A
  • Extremely rare
  • Most androgen secreting adenomas are mixed tumors
Non-functional[1][11][12][13]
  • Asymptomatic
  • Abdominal pain
  • Abdominal distenstion
  • Nausea/vomiting
  • Sub-clinical Cushing syndrome
  • Sub-clinical hyperaldosteroism
  • Asymptomatic
  • Abdominal asymmetry
  • Abdominal mass
  • Sub-clinical Cushing syndrome
  • Sub-clinical hyperaldosteroism
  • N/L
  • ↓ Adrenal hormones
  • ↑ Cortisol (sub-clinical)
  • ↑ Aldosterone (sub-clinical)
  • ↑ Androgens (sub-clinical)
  • Well-defined margins
  • Large monomorphic cells
  • Abundant/foamy cytoplasm
  • Typically resemble normal adrenal histology
  • May see hemorrhage & necrosis
  • Solid, well defined mass (ultrasound)
  • High lipid content and adjacent compression (CT)
  • Hyperintense on in-phase and hypointense on oppose-phase (MRI)
  • Adrenal hormone levels
  • Blood glucose level
  • Plasma catecholamines and urinary metanephrines
  • ARR
  • Immunohistochemical staining
  • N/A
  • 2-fold increased risk for Diabetes mellitus in some studies
  • Work up must exclude Cushing syndrome, pheochromocytoma and adrenal carcinoma
Carcinoma
  • Symptoms of adrenal hormones as mentioned in adrenal adenomas
  • Constitutional symptoms such as cachexia, night sweats, fever
  • Localized symptoms such as abdominal pain, mass, fullness, early satiety
  • Signs of adrenal hormones as mentioned in adrenal adenomas
  • Constitutional
  • Localized signs such as abdominal mass,abdominal distension
  • N/L
  • ↑ Cortisol
  • ↑ Aldosterone
  • ↑ Androgens
Nodular

Hyperplasia

Adrenal mass Clinical manifestations Diagnosis Gold standard Other features
Symptoms Signs Blood & Urine Histopathological Imaging Others

References

  1. 1.0 1.1 1.2 Park JJ, Park BK, Kim CK (June 2016). "Adrenal imaging for adenoma characterization: imaging features, diagnostic accuracies and differential diagnoses". Br J Radiol. 89 (1062): 20151018. doi:10.1259/bjr.20151018. PMC 5258164. PMID 26867466.
  2. Monticone S, Castellano I, Versace K, Lucatello B, Veglio F, Gomez-Sanchez CE, Williams TA, Mulatero P (August 2015). "Immunohistochemical, genetic and clinical characterization of sporadic aldosterone-producing adenomas". Mol. Cell. Endocrinol. 411: 146–54. doi:10.1016/j.mce.2015.04.022. PMC 4474471. PMID 25958045.
  3. Stowasser M, Taylor PJ, Pimenta E, Ahmed AH, Gordon RD (May 2010). "Laboratory investigation of primary aldosteronism". Clin Biochem Rev. 31 (2): 39–56. PMC 2874431. PMID 20498828.
  4. 4.0 4.1 Guerrisi A, Marin D, Baski M, Guerrisi P, Capozza F, Catalano C (2013). "Adrenal lesions: spectrum of imaging findings with emphasis on multi-detector computed tomography and magnetic resonance imaging". J Clin Imaging Sci. 3: 61. doi:10.4103/2156-7514.124088. PMC 3935261. PMID 24605256.
  5. Stratakis CA (2008). "Cushing syndrome caused by adrenocortical tumors and hyperplasias (corticotropin- independent Cushing syndrome)". Endocr Dev. 13: 117–32. doi:10.1159/000134829. PMC 3132884. PMID 18493137.
  6. Zilbermint M, Stratakis CA (June 2015). "Protein kinase A defects and cortisol-producing adrenal tumors". Curr Opin Endocrinol Diabetes Obes. 22 (3): 157–62. doi:10.1097/MED.0000000000000149. PMC 4560837. PMID 25871963.
  7. Wei J, Li S, Liu Q, Zhu Y, Wu N, Tang Y, Li Q, Ren K, Zhang Q, Yu Y, An Z, Chen J, Li J (April 2018). "ACTH-independent Cushing's syndrome with bilateral cortisol-secreting adrenal adenomas: a case report and review of literatures". BMC Endocr Disord. 18 (1): 22. doi:10.1186/s12902-018-0250-6. PMC 5913873. PMID 29685132.
  8. Arnold DT, Reed JB, Burt K (January 2003). "Evaluation and management of the incidental adrenal mass". Proc (Bayl Univ Med Cent). 16 (1): 7–12. PMC 1200803. PMID 16278716.
  9. Rodríguez-Gutiérrez R, Bautista-Medina MA, Teniente-Sanchez AE, Zapata-Rivera MA, Montes-Villarreal J (2013). "Pure androgen-secreting adrenal adenoma associated with resistant hypertension". Case Rep Endocrinol. 2013: 356086. doi:10.1155/2013/356086. PMC 3681270. PMID 23819074.
  10. Zhou WB, Chen N, Li CJ (January 2019). "A rare case of pure testosterone-secreting adrenal adenoma in a postmenopausal elderly woman". BMC Endocr Disord. 19 (1): 14. doi:10.1186/s12902-019-0342-y. PMC 6343319. PMID 30674304.
  11. Lopez D, Luque-Fernandez MA, Steele A, Adler GK, Turchin A, Vaidya A (October 2016). ""Nonfunctional" Adrenal Tumors and the Risk for Incident Diabetes and Cardiovascular Outcomes: A Cohort Study". Ann. Intern. Med. 165 (8): 533–542. doi:10.7326/M16-0547. PMC 5453639. PMID 27479926.
  12. Nieman LK (September 2010). "Approach to the patient with an adrenal incidentaloma". J. Clin. Endocrinol. Metab. 95 (9): 4106–13. doi:10.1210/jc.2010-0457. PMC 2936073. PMID 20823463.
  13. Li B, Guo Q, Yang H, Guan J (January 2013). "Giant non-functional adrenal adenoma: A case report". Oncol Lett. 5 (1): 378–380. doi:10.3892/ol.2012.978. PMC 3525484. PMID 23255953.